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Key messages
What is already known about this subject?
 ► eosinophilic granulomatosis with polyangiitis (egPa) 
current management relies on glucocorticoids and 
immunosuppressive drugs but relapses and high 
glucocorticoid exposure are frequent. rituximab is 
an effective and licensed therapy for granulomatous 
with polyangiitis/microscopic polyangiitis but there 
is a paucity of data from egPa.
What does this study add?
 ► rituximab was associated with reduced disease 
activity and prednisolone requirement in egPa pa-
tients, but relapses occurred despite maintenance 
rituximab.
 ► antineutrophil cytoplasmic antibodies (anca) pos-
itive patients had a longer asthma/ear, nose and 
throat relapse-free survival time and a shorter time 
to remission after rituximab.
How might this impact on clinical practice?
 ► rituximab appears to have a useful role in relapsing 
egPa patients, although the magnitude of benefit 
may associate with anca status and clinical profile 
(vasculitic versus eosinophilic).
AbstrAct
Introduction eosinophilic granulomatosis with polyangiitis 
(egPa) is a subset of antineutrophil cytoplasmic 
antibodies (anca) associated vasculitis with distinct 
pathophysiological mechanisms, clinical features and 
treatment responses. rituximab is a licensed therapy 
for granulomatosis with polyangiitis and microscopic 
polyangiitis but there is limited experience of rituximab in 
egPa.
Methods egPa patients from a tertiary centre who 
received rituximab for mostly refractory egPa or in whom 
cyclophosphamide was contra indicated were studied. 
a standardised dataset was collected at time of initial 
treatment and every 3 months for 24 months. response 
was defined as a Birmingham Vasculitis activity Score 
(BVaS) of 0 and partial response as ≥50% reduction in 
BVaS from baseline. remission was defined as a BVaS of 0 
on prednisolone dose ≤5 mg.
Results Sixty-nine patients (44 female) received rituximab 
between 2003 and 2017. improvement (response and 
partial response) was observed in 76.8% of patients at 6 
months, 82.8% at 12 months and in 93.2% by 24 months, 
while relapses occurred in 54% by 24 months, with 
asthma being the most frequent manifestation. the median 
BVaS decreased from 6 at baseline to 1 at 6 months, and 0 
at 12 and 24 months. Prednisolone dose (mg/day, median) 
decreased from 12.5 to 7, 7.5 and 5 at 6, 12 and 24 
months, respectively. anca positive patients had a longer 
asthma/ear, nose and throat (ent) relapse-free survival 
time and a shorter time to remission.
Discussion rituximab demonstrated some efficacy in 
egPa and led to a reduction in prednisolone requirement, 
but asthma and ent relapse rates were high despite 
continued treatment. the anca positive subset appeared 
to have a more sustained response on isolated asthma/
ent exacerbations.
InTRoDuCTIon
Eosinophilic granulomatosis with poly-
angiitis (EGPA) is a rare small-vessel vascu-
litis characterised by eosinophil-rich and 
necrotising granulomatous inflammation, 
frequently associated with asthma and eosin-
ophilia.1 The 2012 International Chapel Hill 
Consensus Conference includes EGPA in 
the antineutrophil cytoplasmic antibodies 
(ANCA) associated vasculitis (AAV) group, 
although only 40% of the patients test posi-
tive for ANCA.2 Although yet to be fully eluci-
dated, the pathogenesis of EGPA has some 
distinctive pathophysiological mechanisms 
from the other AAV disease phenotypes. 
These include an increased interleukin 
(IL)-5 production and consequent increased 
maturation and survival of eosinophils.3 4 A 
predominant Th2 response, as levels of Th2 
cytokines, such as IL-4 and IL-13, are raised 
in EGPA.5 Recommendations for EGPA 
management are often extrapolated from 
experience in the more common AAV 
subgroups (granulomatous with polyangiitis 
(GPA) and microscopic polyangiitis (MPA)), 
and this approach may not be reliable.6 EGPA 
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has been the subject of few randomised controlled trials. 
The MIRRA trial of mepolizumab (A Double-blind, 
Randomised, Placebo-controlled Study to Investigate 
the Efficacy and Safety of Mepolizumab in the Treat-
ment of Eosinophilic Granulomatosis with Polyangiitis 
in Subjects Receiving Standard of Care Therapy), a 
humanised monoclonal antibody that targets IL-5, has 
been the only industry sponsored trial in EGPA and a 
positive result led to an approval for EGPA by the Food 
and Drug Administration (FDA).7 In this trial, mepoli-
zumab led to more accrued weeks of remission than 
placebo (28% vs 3%) and reduction of the mean daily 
dose of prednisolone at week 52 (9.2 mg in the mepoli-
zumab group vs 13.5 mg in the placebo group). Based 
on the long-term observational studies, EGPA patients 
are subgrouped into those with poor prognostic factors 
(such as serum creatinine >140 µmol/L; proteinuria 
>1 g/day; or central nervous system, gastrointestinal 
or myocardial involvement), in whom cyclophospha-
mide and glucocorticoids are recommended and 
those without poor prognostic factors for whom pred-
nisolone with or without an immunosuppressive, such 
as, azathioprine is recommended.8–10 Despite therapy 
most patients remain glucocorticoid dependent with a 
relapsing/remitting course as the glucocorticoid dose 
is weaned and acquire a high cumulative exposure to 
glucocorticoids and immunosuppressive agents with 
their attendant complications. There is a clear need for 
newer therapies that achieve sustained remission with 
low or no concomitant glucocorticoids requirement.
Rituximab, an anti‐CD20 B‐cell depleting chimeric 
monoclonal antibody, has proven efficacy for remission 
induction and maintenance in GPA and MPA.11–13 The 
rationale for rituximab in EGPA comes from the pres-
ence of ANCA in 40% of the patients, and similarities 
in the vasculitic features between EGPA and GPA/MPA, 
which reflect B-cell involvement in disease pathogenesis.2 
In distinction from GPA/MPA, EGPA patients suffer 
non-vasculitic eosinophilic manifestations, including 
asthma, naso-sinus disease and myocarditis where the 
rationale for rituximab is weaker.
However, preliminary studies have found reductions in 
T-cell derived IL-5 production with rituximab.14 Also, a 
strong IgG4 immune response in EGPA, irrespective of 
the ANCA status, has been described15 and rituximab 
has proved beneficial for IgG4-related syndromes.16 17 
Finally, previous studies have suggested a clinical benefit 
for rituximab in EGPA, but they were limited by small 
patient numbers and a short treatment duration.18 19 This 
study aimed to assess the longer term efficacy and safety 
of rituximab in EGPA.
PaTIenTs anD MeTHoDs
We performed a retrospective study of patients with 
EGPA treated with rituximab in a single tertiary centre, 
the Vasculitis and Lupus clinic, Cambridge, UK.
Rituximab treatment protocols
The indications for rituximab in EGPA were either 
active refractory or frequently relapsing disease, defined 
according to the patient’s physician assessment or a 
contraindication to cyclophosphamide. Five patients 
received a single course of rituximab. The initial treat-
ment protocol consisted, in 64 patients, of two doses of 
1000 mg 2 weeks apart, with only five patients receiving a 
dose of 375 mg/m2/week for 4 weeks. Fifty-nine patients 
(86%) were retreated every 6 months with a 1000 mg 
dose, with a minority of the patients (14%) being 
retreated every 4 (minimum) or 12 (maximum) months. 
Patients received premedication with intravenous hydro-
cortisone 100 mg, intravenous chlorpheniramine 10 mg 
or diphenhydramine 50 mg and oral acetaminophen 
1 g before each rituximab infusion; and pneumocystis 
prophylaxis with sulfamethoxazole/trimethoprim for 6 
months.
Data collection
Data collection included baseline demographics, labo-
ratory parameters and Disease Extent Index (DEI)20 at 
time of ﬁrst rituximab and every 3 months for 24 months. 
In the DEI, asthma was considered as a marker for lung 
involvement. Data about previous immunosuppressive 
drugs as well as prednisolone doses were collected. A 
positive ANCA result was recorded if either immunoﬂu-
orescence or ELISA for either proteinase-3 or myelop-
eroxidase ANCA were positive from the time of diag-
nosis to the time of first treatment. Disease activity was 
assessed using the Birmingham Vasculitis Activity Score 
(BVAS) V.3.21 In BVAS, symptomatic asthma was scored 
as ‘wheeze’. Refractory asthma and ear, nose and throat 
(ENT) disease was defined as asthma or ENT symptoms 
flares at steroid tapering justifying an increase of the 
steroid dose and/or a change of immunosuppressive 
drug.
treatment outcome and adverse events
The response to therapy was judged clinically by the 
treating physician. Remission was defined as a BVAS 
of 0 on a daily prednisolone dose ≤5 mg. Response to 
treatment was defined as a BVAS of 0 independent of 
glucocorticoid dose.22 Partial response was deﬁned as a 
reduction of ≥50% in BVAS compared with the baseline 
score.
Relapses were defined as a recurrence of signs or symp-
toms leading to an increase in BVAS and an increase 
in prednisolone dose by ≥5 mg or institution of intra-
venous glucocorticoids, intravenous aminophylline or 
new immunosuppressive agent. An initial remission was 
not required to have a relapse. Mild hypogammaglobu-
linaemia was deﬁned as an IgG level between 5 and 6.9 
g/L, moderate between 3 and 4.9 g/L and severe if IgG 
level was <3 g/L. Severe infections were those resulting in 
hospitalisation, prolongation of existing hospital stays or 
requiring intravenous antibiotics.
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Table 1 Baseline demographics and clinical characteristics 
of 69 patients with eosinophilic granulomatosis with 
polyangiitis treated with rituximab
Sex Female/Male 44/25
Age at first rituximab, median (IQR) 51 (39.5–58.0)
ANCA status (historical or at treatment onset), no 
of patients (%)
 
Positive (including immunofluorescence) 24 (34.8)
Negative (including immunofluorescence) 45 (65.2)
Positive C-or P-ANCA (only immunofluorescence) 20 (29.0)
PR3-ANCA 9 (13.0)
MPO-ANCA 16 (23.2)
No of prior immunosuppressive therapies: 
mean±SD; median (IQR)
  2.37±1.46; 2 (1–3)
Immunosuppressive drugs prior to rituximab, no 
of patients (%)
 
Cyclophosphamide   34 (49.3)
Azathioprine   46 (66.7)
Mycophenolate mofetil 39 (56.5)
Methotrexate 17 (24.6)
Intravenous immunoglobulin 11 (15.9)
Alemtuzumab 3 (4.3)
Etanercept 1 (1.4)
Infliximab 2 (2.9)
Mepolizumab 1 (1.4)
Omalizumab 1 (1.4)
No previous immunosuppressive treatment 4 (5.8)
DEI score at first rituximab treatment, mean±SD 6±3.1
BVAS at first rituximab, mean±SD; median (IQR) 7.05 (±5.22); 6.0 
(3.0–8.5)
Organ involvement according to DEI, no of 
patients (%)
 
Lung (including asthma) 68 (98.6)
Ear, nose and throat (ENT) 61 (88.4)
Arthralgia/arthritis 32 (46.4)
Skin 41 (59.4)
Peripheral nervous system 40 (58.0)
Renal 11 (15.9)
Gastrointestinal tract (including biliary system) 12 (17.4)
Heart 15 (21.7)
Eyes 8 (11.6)
Central nervous system 3 (4.3)
Urogenital tract 2 (2.9)
Refractory asthma 46 (66.6)
Refractory ENT disease 23 (33.3)
ANCA, anti-neutrophil cytoplasmic antibodies; BVAS, Birmingham Vasculitis 
Activity Score; DEI, Disease Extent Index; MPO, myeloperoxidase; PR3, 
proteinase-3.
statistical analyses
Since the usual interval dosing of rtuximab is every 6 
months, response, disease activity, prednisolone dose, 
laboratory tests and infections were considered in the 
analysis until 6 months after last treatment, and reasons 
for treatment discontinuation were presented separately. 
Continuous variables were presented as medians and 
IQRs unless otherwise stated. Differences in continuous 
variables were tested by the non-parametric Sign test. 
Kaplan-Meier curves were used to illustrate the proba-
bility of remaining relapse-free according to ANCA status 
and to evaluate time to remission. A Pearson’s X2 test 
was applied to evaluate the relationship between cate-
gorical variables. A p<0.05 was considered signiﬁcant for 
all analyses. Statistical analyses were performed using the 
Statistical Package for the Social Sciences, SPSS V.22.0 for 
Windows (IBM). For graphical representations, MedCalc 
V.18.6 and the BioVinci V.1.3.3 were used.
ResulTs
Between 2003 and 2017, 140 patients with EGPA had 
been reviewed by the clinic. Seventy-two were treated 
with rituximab, but only 69 patients were considered for 
this analysis (table 1). Two were excluded due to follow 
up in other hospitals, and one because he had received 
alemtuzumab 1 month before rituximab.
The median length of treatment (time between first 
and last infusion during the follow-up period) was 23 
months (IQR 12.5–24.0 months) and the survival rate 
of rituximab was 84.8% at 12 months and 68.4% at 24 
months. During the follow-up period, the median cumu-
lative dose of rituximab was 2 g (IQR 2.0–2.0 g) for induc-
tion and 3 g (IQR 2.0–3.0) for maintenance.
Response
Figure 1 describes the percentage of responders, partial 
responders and non-responders. Patients who discon-
tinued treatment were only considered in the categories 
until 6 months following last treatment. Moreover, at the 
time of the analysis, some patients still receiving treat-
ment had insufficient treatment duration to be consid-
ered in the analysis at 18 months (5 patients) and at 24 
months (10 patients).
Five patients received a single course of rituximab. 
Three had no response and were not followed further, 
and two, who responded, received maintenance treat-
ment with mycophenolate mofetil and prednisolone or 
prednisolone alone. Before 12 months, a further five 
discontinued rituximab due to an insufficient treatment 
response, and before 18 months, a further five discon-
tinued rituximab with sustained response in four, and 
an insufficient response in one. The rates of discontin-
uations due to insufficient response were slightly higher 
than the rates of discontinuation due to good response.
Response to treatment was achieved in 40.6% of 
patients by 6 months and this rose to 77.3% by 24 
months. Improvement (responses and partial responses) 
was observed in 76.8% of patients at 6 months, 82.8% at 
12 months, in 90.7% at 18 months and in 93.2% by 24 
months.
At 6 months, 13.3% and 29.2% of ANCA negative and 
ANCA positive patients, respectively, were on remission, 
rising to 23.1% and 34.8% at 12 months, but the differ-
ences according to ANCA status were not statistically 
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Figure 1 Treatment response by percentage of patients 
divided by three categories: no response, partial response 
and response. The total number of patients considered by 
months are presented over columns.
Figure 2 Survival without achieving remission, including 
vasculitis, asthma and ENT involvement remission. the 
median time to remission was 15 months in the ANCA 
positive group and 24 months in the ANCA negative group. 
Estimation was limited to the largest survival time evaluated 
(24 months after starting treatment), p=0.02 (log-rank test). 
ANCA, anti-neutrophil cytoplasmic antibodies; ENT, ear, nose 
and throat.
Figure 3 Median (IQR) of the Birmingham Vasculitis Activity 
Score (BVAS) at baseline and every 3 months (M) from 
baseline. Baseline: 6.0 (3.0–8.5), N=69 vs 6 months: 1.0 (0.0–
3.0), N=69, z=6.9 vs 12 months: 0.0 (0.0–2.0), N=64, z=6.54 
vs 18 months: 0 (0.0–0.25), N=54, z=6.49 vs 24 months: 0.0 
(0.0–0.0), N=44, z=6.25, p<0.001. Boxes represent IQRs and 
the median. Lower and upper limits represent the minimum 
and maximum, respectively.
Figure 4 Median (IQR) prednisolone/prednisone dose (mg/
day) at baseline, and every 3 months after initial rituximab 
treatment. Baseline: 12.5 (10.0–20.0), N=69 vs 6 months: 7 
(5–10.75), N=69, z=5.58 vs 12 months: 7.25 (IQR 4.75–10.0), 
N=64, z=4.76 vs 18 months: 5 (2.0–10.0), N=54, z=5.58 vs 24 
months: 5 (3.25–10.0), N=44, z=4.8, p<0.001.
significant (exact Pearson test 0.19 at 6 months and 0.38 
at 12 months).
The median time to remission was shorter in the ANCA 
positive group than the ANCA negative group (p=0.02), 
with a median time to remission of 15 months in the 
former and 24 months in the latter (figure 2).
The median BVAS at baseline was 6 (IQR 3–8.5) and 
decreased to 1 (IQR 0–3) at 6 months, to 0 (IQR 0–2) at 
12 months and to 0 (IQR 0–0) at 24 months (figure 3). 
Of the 64 patients who received a second treatment with 
rituximab at 6 months, only three had a higher BVAS 
score at 12 months than at baseline and four had no 
change in BVAS at 12 months. At 24 months, of the 44 
patients evaluated, two had the same BVAS as at baseline 
and none had a higher BVAS. In the two patients with the 
same BVAS at baseline and 24 months, rituximab treat-
ment allowed prednisolone dose reduction.
Prednisolone dose and other concomitant treatments
At baseline, 6, 12, 18 and 24 months, 4.3%, 7.2%, 9.3%, 
20.4% and 15.9% were glucocorticoid free, respectively. 
The median daily dose of prednisolone was 12.5 mg at 
baseline (IQR 10.0–20.0) and decreased to 7 mg (IQR 
5–10.75) at 6 months, to 7.25 mg (IQR 4.75–10.0) at 
12 months and to 5 mg (IQR 3.25–10) at 24 months 
(figure 4). Five patients required treatment with intra-
venous steroids beyond standard rituximab infusions for 
asthma in three, skin lesions in one and worsening poly-
neuropathy in other.
Twelve of the 69 patients were treated with a combina-
tion of rituximab and an additional immunosuppressive 
agent. In 11, the immunosuppressive agent was added 
during rituximab treatment (median of 15 months after 
starting treatment) in the context of relapsing disease in 
seven in refractory disease in four. In one, the additional 
immunosuppressive agent was not suspended when ritux-
imab was initiated nor throughout treatment.
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Table 3 Manifestations driving relapse during rituximab 
treatment
Manifestations driving relapse, mean relapses/person 
(% persons who suffered at least one relapse)
Asthma/lung 0.68±1.13 (43.5)
ENT 0.17±0.38 (17.4)
Skin 0.26±0.8 (13.0)
Kidney 0 (0)
Heart 0.03±0.169 (2.9)
Joint 0.16±0.41 (14.5)
Digestive 0.03±0.17 (2.9)
Neurological 0.01±0.12 (1.4)
ENT, ear, nose and throat.
Figure 5 Kaplan-Meier curve representing isolated asthma/
ENT relapse-free survival (months) after starting rituximab. 
Estimation was limited to the largest survival time evaluated 
(36 months after starting treatment), p=0.04 (log-rank test). 
ANCA, antineutrophil cytoplasmic antibodies; ENT, ear, nose 
and throat.
Table 2 Laboratory data at entry (time of first rituximab infusion), at 12 and 24 months
Entry, median 
(IQR)
(N=69)
12 months
(N=64)
24 months
(N=44)
IgG, g/L 8.07 (6.66–9.66) 7.9 (6.04–8.77) z=0.452, 
p=0.651
6.95 (5.76–8.52)
z=2.84, p<0.005
Total peripheral eosinophil count, x109/L 0.26 (0.11–0.77) 0.21 (0.10–0.55) z=0.62, 
p=0.53
0.22 (0.13–0.34) z=0, p=1.00
C reactive protein, mg/L 4.00 (3.00–9.00) 4.00 (3.00–8.00)
Z=3.2, p=0.75
4.00 (2.00–8.00) z=0, p=1.000
Erythrocyte sedimentation rate, mm/hour 9.00 (6.00–19.50) 8.00 (5.00–14.00) z=2.96, 
p<0.005
7.00 (5.50–12.00) z=−2.46, 
p=0.01
laboratory tests
No change was observed in C reactive protein, erythrocyte 
sedimentation rate and eosinophil count throughout the 
treatment period (table 2). The median value at baseline 
of these parameters was within the normal ranges. The 
median IgG level at baseline was 8.07 g/L without major 
changes at 12 months. However, at 24 months, a median 
decrease to 6.95 g/L was noted. Hypogammaglobuli-
naemia rates at baseline, 6 and 12 months were similar 
(about 15%), but increased to 20.5% and 38.7% at 18 and 
24 months, respectively. Rates of mild hypogammaglobu-
linaemia were 7.3%, 10.6%, 8.3%, 13.6% and 32.3% at 0, 
6, 12, 18 and 24 months, respectively. Rates of moderate 
hypogammaglobulinaemia were 7.3%, 4.5%, 6.7%, 6.8% 
and 6.5% at 0, 6, 12, 18 and 24 months, respectively. 
None of the patients developed severe hypogammaglob-
ulinaemia during the evaluated period. During mainte-
nance therapy, no patient received treatment with intra-
venous immunoglobulin (IG) for recurrent infections or 
hypogammaglobulinaemia.
Relapses
During the first 24 months after starting treatment, 54% 
of the patients suffered at least one relapse on treat-
ment. 29.7% of these relapses occurred after achieving 
remission, and thus were considered as having relapsing 
disease. The mean number of relapses per patient was 
0.9±1.27. Relapses were mainly driven by asthma, with 
43.5% of the patients suffering at least one asthma 
relapse (table 3). ENT relapses were the second most 
frequent, followed by joint and skin manifestations. Skin 
involvement was usually described as erythematous macu-
lopapular without purpura but was not systematically 
recorded and not confirmed by skin biopsy. None of the 
11 patients with renal disease relapsed during treatment 
with rituximab. Only one patient presented with neuro-
logical features, suggestive of worsening polyneuropathy. 
Central nervous system vasculitis was not reported.
Regarding isolated asthma/ENT relapses (figure 5), 
ANCA negative patients had a shorter relapse-free 
survival time compared with ANCA positive patients, 
(p=0.04), but no difference was seen between both 
groups regarding vasculitis relapses (figure 6).
severe infections and mortality
In the first 24 months from baseline, 11 patients (16%) 
suffered at least one severe infection during treatment, 
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Figure 6 Kaplan-Meier curve representing vasculitis 
relapse-free survival (months) after starting rituximab (log-
rank test). Estimation was limited to the largest survival time 
evaluated (36 months after starting treatment), p=0.82 (log-
rank test). ANCA, antineutrophil cytoplasmic antibodies.
Table 4 Type of severe infections reported during 
rituximab treatment
Type of infections, N (%)
Respiratory tract 12 (71)
Urogenital tract 3 (17.6)
Mastoiditis 1 (5.9)
Cellulitis 1 (5.9)
with four (5.8%) of them suffering two severe infections 
and one (1.4%) suffering three severe infections. Severe 
infections were observed in 12.32 per 100 patients-year. In 
some of these, treatment was delayed, but infection was 
not associated with treatment withdrawal. Infections were 
mainly localised to the respiratory tract, corresponding 
to 71% of all severe infections (table 4). No opportun-
istic infections were reported. Deaths of any cause did 
not occur during the first 24 months of follow-up.
DIsCussIon
We have analysed the efficacy and safety of rituximab in 
a cohort of 69 patients with EGPA. The rates of positive 
responses and the corticosteroid sparing effect seen after 
rituximab strengthens the argument for a useful thera-
peutic effect of this drug.
The outcomes in our study were analysed until 6 
months after last rituximab, corresponding to our usual 
interval dosing of the drug and the expected duration 
of the treatment effect. Although rituximab may have 
a prolonged effect on the disease beyond 6 months, we 
aimed to look at the effect of the treatment only during 
the period of administration to avoid potential bias 
related to other treatments, as some of the patients who 
failed to respond were later exposed to other treatments. 
Most followed the 6 months repeat dose rituximab 
regimen for 24 months with nine (13%) discontinuing 
the drug due to an insufficient response and six (8.7%) 
due to a good treatment response.
Reductions in disease activity, as measured by BVAS, 
followed treatment with rituximab. At 6 months, 41% 
of the patients achieved a response and 36% achieved 
a partial response. Response rates, however, tended to 
increase in our cohort until 24 months, with 77% of the 
patients achieving a response.
The rates of remission seen in our study were lower 
than that seen following Rituximab in GPA/MPA, which 
range from 64% to 75% at 6 months.23 24 ANCA positive 
patients had a shorter time to remission compared with 
the ANCA negative subgroup. Higher remission rates 
were seen in the ANCA positive group. ANCA positivity 
has previously been associated with a higher remission 
rate at 12 months in EGPA after rituximab.18 This may 
suggest that ANCA positive EGPA patients may have 
a phenotype more similar to GPA and MPA and may 
benefit more from B-cell depletion therapies.
Rituximab permitted prednisolone dose reductions 
with the median daily prednisolone at baseline of 12.5 
mg/day falling to 7.25 at 12 months and to 5 mg at 24 
months. However, only a few patients were steroid free. 
Eleven patients required addition of another immuno-
suppressive during follow-up, which may overestimate 
the efficacy of rituximab. However, these results are still 
encouraging as EGPA patients are frequently exposed 
to high doses of prednisolone and susceptible to related 
complications. For instance, in a large French study, 236 
out of 280 EGPA patients required long-term high pred-
nisolone doses (mean dose 12.9±12.5 mg/day).25
We did not observe any change with treatment in 
the C reactive protein, erythrocyte sedimentation rate 
and peripheral eosinophil counts. This is likely due 
to the fact that the median values at time of first treat-
ment were within the normal ranges, as a result of high 
previous prednisolone doses and other concomitant 
immunosuppression, as these were mainly refractory and 
relapsing patients. A reduction of IgG levels was seen 
by 18 months and worsened by 24 months, although, 
20.5% of the patients had low levels at baseline reflecting 
prior therapy. The susceptibility of AAV patients to ritux-
imab-induced hypogammaglobulinaemia has been noted 
in other studies.26
We found a high rate of relapses during treatment 
with rituximab, with about half of the patients relapsing 
during the evaluation period, much higher than seen 
with similar repeat dose rituximab maintenance dosing 
in GPA/MPA populations.27 However, our cohort was 
mainly relapsing and/or refractory patients and, in other 
EGPA populations, relapse rates as high as 81.1% have 
been reported.28 ANCA positivity was associated with 
longer asthma/ENT relapse-free survival time and a 
shorter time to remission after rituximab. Whether this 
represents a drug effect or reflects the natural history 
of the disease, with ANCA positive patients having more 
frequent asthma and/or ENT flares than ANCA negative 
patients, could not be assessed in our study. No difference 
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was found regarding vasculitis relapse-free survival time 
between ANCA positive and ANCA negative patients. 
Interestingly, other studies have showed higher relapse-
free survival rates for ANCA negative patients when 
treatment modality was not considered,25 29 even though 
other studies failed to show any difference.2 28 30 This may 
indicate a greater benefit of rituximab in the treatment 
of ANCA positive patients. In a smaller study, treatment 
response to rituximab was independent of ANCA status.19
The relapses in our cohort were mainly driven by 
asthma, followed by ENT disease. Of note, asthma 
relapses were only included if they were associated with 
change in treatment, in line with EGPA task force recom-
mendations which recognise that transient loss of asthma 
control with, for example, a viral infection are common 
and do not necessarily require therapeutic changes.31 
Renal flares were not observed in any patient during 
treatment with rituximab. Moreover, skin flares were 
usually described as erythematous and not vasculitic 
with purpura. This suggests that rituximab may be better 
in preventing vasculitis-mediated relapses, rather than 
preventing eosinophilic mediated relapses.
The rate of infections in our study was similar to the rate 
of infections in other studies of patients with AAV treated 
with rituximab.32 It is important to note that the infec-
tive risk will have been reduced by avoiding concurrent 
rituximab and immunosuppressive treatment and the 
prednisolone reduction that was seen after rituximab. In 
a smaller study comprising 14 patients with EGPA treated 
with rituximab, none of the patients developed a major 
infection during the first 36 months after the first treat-
ment, although only three patients were retreated with 
rituximab after induction.19
Alternative treatment options for refractory EGPA 
have included intravenous IG, plasma exchange and 
alpha-interferon with support only from small observa-
tional studies.33 34 Mepolizumab led to clinically useful 
effects in around three-quarters of patients in the MIRRA 
trial with particular benefit shown for the non-vasculitic 
eosinophilic manifestations of asthma and naso-sinus 
disease.7 The greater success of rituximab for the ANCA 
positive EGPA subgroup and failure to control asthma 
relapses points to a differentiation compared with mepo-
lizumab and the potential for personalisation of therapy 
according to these parameters. A recent genome-wide 
association study of EGPA revealed genetic and clinical 
differences between the ANCA positive and the ANCA 
negative subsets, supporting different pathogenesis 
between these subsets and consequently different thera-
peutic strategies.35
Our study was limited by its retrospective nature, with 
the potential for missing data and inaccurate BVAS assess-
ment. BVAS itself is a semiobjective tool that has not been 
thoroughly validated in EGPA, although has appeared to 
perform well in previous EGPA studies. The relatively 
short follow-up after last rituximab means that we have 
not been able to report in detail on the longer term effi-
cacy benefits and safety risks of rituximab. However, over 
time the difference between discontinuation rates due 
to insufficient response compared with discontinuation 
rates due to response was low, therefore, we would not 
expect this to impact our conclusions. The glucocorticoid 
sparing effect is difficult to evaluate without a control 
group. Lastly, there was some heterogeneity in the ritux-
imab treatment schedules. However, in a previous study, 
no differences in treatment responses were observed 
between patients who received rituximab 375 mg/m2/
week for 4 weeks or those who received rituximab two 
doses of 1 g at 2-week intervals, but no data were avail-
able regarding relapses.18 While the dose regimen may 
not influence the results, a scheduled rituximab-mainte-
nance treatment may reduce the relapse rate compared 
with rituximab given on demand for relapses, as suggested 
recently by an Italian study.36 The strengths of this study 
are presenting a long-term data in the largest sample size 
of patients with EGPA treated with rituximab and the lack 
of selection bias, due to evaluation of a complete cohort 
of EGPA patients. We also present the first concise data 
on relapses in patients treated with rituximab.
We conclude that, in a real-world tertiary vasculitis 
clinic setting rituximab was associated with decreases in 
EGPA disease activity and prednisolone requirement. 
However, the asthma and ENT relapse rates were high 
despite repeat rituximab dosing and the development 
of hypogammaglobulinaemia a safety concern. The 
ANCA positive subset appeared to have a more sustained 
response on isolated asthma/ENT exacerbations.
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